drugset / Trial / NCT00759564

A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function

NCT00759564

Phase 1 Completed 29 enrolled Pfizer
Non-randomizedCrossoverOpen-label

Summary

This study will evaluate what effect renal dysfunction has on a drug that has an intravenous (CP-70,429) and an oral form (PF-03709270).

Timeline

Start
2008-11
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Sulopenem Small molecule 800 mg Intravenous
Subject sulopenem etzadroxil Small molecule 1000 mg Oral

Indications